Learn More About This Trial
Recruiting Trials
clinical trial
Chronic Spontaneous Urticaria
RECRUITING
Phase 3 | Injection | 24 week treatment period | 8 week safety follow up
For children and adults (≥6 to 80) with chronic spontaneous urticaria (subcutaneous study drug)
clinical trial
Hidradenitis Suppurativa
RECRUITING
Phase 2 | Injection | 16 week treatment period | 8 week safety follow up
For adults (≥18) with moderate to severe hidradenitis suppurativa (subcutaneous study drug)
clinical trial
Hidradenitis Suppurativa
RECRUITING
Phase 2 | Injection | 24 week treatment period | 4 week safety follow up
For adults (≥18) with moderate to severe hidradenitis suppurativa (subcutaneous study drug)
Coming Soon Trials
clinical trial
Atopic Dermatitis
COMING SOON
Phase 2B | Injection | 16 week treatment period | 17 week safety follow up
For adults (≥18) with moderate to severe atopic dermatitis (subcutaneous study drug)
clinical trial
Atopic Dermatitis
COMING SOON
Phase 2B | Injection | 36 week treatment period | 20 week safety follow up
For adolescents (≥12 to <18) with moderate to severe atopic dermatitis (subcutaneous study drug)
clinical trial
Atopic Dermatitis
COMING SOON
Phase 3 | Injection | 24 week treatment period | 8 week safety follow up
For adults (≥18) with moderate to severe atopic dermatitis (subcutaneous study drug).
Not Recruiting Trials
clinical trial
Atopic Dermatitis
NOT RECRUITING
Phase 3 | Topical cream | 52 week treatment period | 4 week safety follow up
For children (≥ 2 and < 12 years) with atopic dermatitis (topical study drug)
clinical trial
Atopic Dermatitis
NOT RECRUITING
Observational study | Injection | 60 month observation period
For patients starting biologic treatment of moderate to severe atopic dermatitis (subcutaneous study drug)
clinical trial
Chronic Inducible Cold Urticaria
NOT RECRUITING
Phase 3 | Injection | 24 week treatment period | 8 week safety follow up
For adults and adolescents (≥12 – 80) with chronic inducible cold urticaria (subcutaneous study drug)
clinical trial
Atopic Dermatitis
NOT RECRUITING
Phase 3 | Topical cream | 52 week treatment period | 4 week safety follow up
For children (≥ 2 and < 12 years) with atopic dermatitis (topical study drug)
clinical trial
Atopic Dermatitis
NOT RECRUITING
Observational study | Injection | 60 month observation period
For patients starting biologic treatment of moderate to severe atopic dermatitis (subcutaneous study drug)
clinical trial
Chronic Inducible Cold Urticaria
NOT RECRUITING
Phase 3 | Injection | 24 week treatment period | 8 week safety follow up
For adults and adolescents (≥12 – 80) with chronic inducible cold urticaria (subcutaneous study drug)
clinical trial
Chronic Spontaneous Urticaria
NOT RECRUITING
Phase 2B | Injection | 16 week treatment period | 16 week safety follow up
For adults (≥18 to 80) with chronic spontaneousurticaria (subcutaneous study drug)
clinical trial
Plaque Psoriasis
NOT RECRUITING
Observational study | Injection | 60 month observation period
For patients starting biologic treatment of moderate to severe chronic plaque psoriasis (subcutaneous study drug)
clinical trial
Plaque Psoriasis
NOT RECRUITING
Observational study | Injection | 37 month observation period
For patients starting biologic treatment of moderate to severe plaque psoriasis (subcutaneous study drug)